# A Study of NeoRecormon (Epoetin Beta), CellCept (Mycophenolate Mofetil) and Prednisone in Patients With Low or Intermediate Myelodysplastic Syndromes.

> **NCT00551291** · PHASE2 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 10 (actual)

## Conditions studied

- Myelodysplastic Syndromes

## Interventions

- **DRUG:** Mycophenolate mofetil
- **DRUG:** Prednisone
- **DRUG:** Erythropoietin Beta

## Key facts

- **NCT ID:** NCT00551291
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-08
- **Primary completion:** 2009-06
- **Final completion:** 2009-06
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2016-07-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00551291

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00551291, "A Study of NeoRecormon (Epoetin Beta), CellCept (Mycophenolate Mofetil) and Prednisone in Patients With Low or Intermediate Myelodysplastic Syndromes.". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00551291. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*